Auriga Laboratories Announces FDA Approval Of Liquadd (TM) Oral Solution For The Treatment Of ADHD And Upcoming Product Launch
Mar 14th 2008Drug InformationADHD
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd? (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD). The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
